Otrivin

What Is Otrivin and What Is It Used For?

Otrivin belongs to a pharmacological family of imidazoline derivatives that includes oxymetazoline, naphazoline and tetrahydrozoline. Its active substance, xylometazoline hydrochloride, is a direct-acting sympathomimetic amine that selectively binds to alpha-adrenergic receptors on vascular smooth muscle. When the receptors are activated, the blood vessels within the swollen nasal mucosa constrict. This reduces mucosal blood flow, decreases tissue edema and fluid transudation, and in turn opens up the nasal passages for air to flow more freely. Unlike oral decongestants such as pseudoephedrine, xylometazoline acts locally at the site of application and therefore has a much smaller systemic footprint when used correctly.

Because of its rapid onset and prolonged duration of action, xylometazoline has become one of the most widely used topical nasal decongestants worldwide. A single dose typically produces a noticeable improvement in nasal airflow within 5 to 10 minutes, with the peak decongestant effect reached at approximately 1 hour and a clinically relevant duration of up to 10 to 12 hours. This pharmacodynamic profile allows most patients to manage symptoms with only one or two sprays per day, which helps minimize cumulative exposure and reduces the risk of rebound phenomena.

Clinically, Otrivin 1 mg/ml is indicated for the short-term symptomatic treatment of nasal congestion associated with a range of upper respiratory tract conditions. These include the common cold (acute viral rhinitis), allergic rhinitis (seasonal and perennial forms, including hay fever), vasomotor rhinitis and acute sinusitis. In these contexts, decongesting the nasal mucosa not only relieves the subjective sensation of a blocked nose but also improves ventilation of the paranasal sinuses and may allow other treatments — such as intranasal corticosteroids or saline irrigations — to reach deeper mucosal surfaces.

Otrivin is also prescribed as an adjunct in acute otitis media (middle ear infection), where it helps restore patency of the Eustachian tube. By shrinking the mucosa around the Eustachian tube opening in the nasopharynx, xylometazoline can facilitate drainage of middle ear fluid and equalize pressure, potentially reducing pain and the risk of complications. Similarly, Otrivin may be used before diagnostic procedures such as rhinoscopy or nasoendoscopy to improve visualization of the nasal cavity and sinus openings.

The product is supplied as a clear, colorless to slightly yellow nasal solution, usually in a metered-dose pump spray bottle or in dropper bottles. Each metered spray typically delivers approximately 140 micrograms of xylometazoline hydrochloride. Formulations may be available both with and without preservatives; preservative-free versions are generally preferred for patients sensitive to benzalkonium chloride or who require frequent administration over longer periods under medical supervision.

What Should You Know Before Using Otrivin?

Before beginning treatment with Otrivin, it is important to review your current medical conditions, medications, and allergies with your healthcare provider or pharmacist. Although xylometazoline is considered a well-tolerated medication when used for short periods at recommended doses, its sympathomimetic activity means that it is not appropriate for all patients. Specific conditions raise the risk of clinically significant adverse effects, either locally (within the nose) or systemically (through minor but real absorption into the bloodstream).

Contraindications

Otrivin must not be used in any of the following situations:

• Hypersensitivity to xylometazoline hydrochloride or to any of the excipients in the nasal solution, including benzalkonium chloride preservative where present.
• Angle-closure (narrow-angle) glaucoma, because sympathomimetic agents can precipitate an acute attack by dilating the pupil and further narrowing the drainage angle of the eye.
• After transsphenoidal hypophysectomy or any other neurosurgical procedure that exposes the dura mater, due to the theoretical risk of CSF leak contamination and altered intracranial pressure.
• Dry inflammatory rhinitis (rhinitis sicca) and atrophic rhinitis, where further vasoconstriction may worsen mucosal dryness and bleeding.
• In children under 12 years for the 1 mg/ml strength. A lower 0.5 mg/ml formulation exists for pediatric use from 2 to 11 years, and specialized infant formulations for those under 2 years require medical supervision.

Warnings and Precautions

Cardiovascular conditions. Xylometazoline can cause small but real increases in heart rate and blood pressure, particularly if used at higher-than-recommended doses or if systemic absorption is increased by inflamed or damaged nasal mucosa. Caution is therefore advised in patients with hypertension, coronary artery disease, cardiac arrhythmias, advanced arteriosclerosis, aortic aneurysm, or a history of myocardial infarction. Your prescriber will weigh the benefits of decongestion against these risks and may prefer alternative treatments such as intranasal saline, corticosteroids or antihistamines.

Endocrine and metabolic conditions. Caution should be exercised in patients with hyperthyroidism, diabetes mellitus, pheochromocytoma, and benign prostatic hyperplasia (BPH) with urinary retention. Sympathomimetic activity can interact with these conditions by altering metabolic, hormonal or smooth muscle responses. Similarly, patients with porphyria or a history of severe anxiety or insomnia sensitive to stimulants should discuss the risk-benefit balance with their healthcare provider.

Pediatric considerations. Children are more susceptible to systemic effects from intranasal xylometazoline due to higher absorption relative to body weight. Accidental ingestion of the nasal solution — particularly in young children — has been associated with rare but potentially serious events including marked drowsiness, pallor, miosis, bradycardia, hypothermia, respiratory depression and, in very rare cases, coma. Always store the bottle out of reach of children and use only age-appropriate strengths.

Length of treatment. Even within the 7–10 day limit, treatment should be stopped as soon as symptoms improve. Reducing the number of daily applications before complete discontinuation may help prevent rebound congestion. Patients who require longer-term management of nasal congestion — for example, because of chronic allergic rhinitis, sinusitis or nasal polyposis — should be transitioned to a more appropriate long-term therapy such as an intranasal corticosteroid.

Pregnancy and Breastfeeding

Pregnancy. Xylometazoline should be used during pregnancy only if the expected benefit to the mother clearly outweighs the potential risk to the fetus. There is limited but generally reassuring clinical experience with intranasal xylometazoline at recommended doses, and systemic absorption is low. However, because xylometazoline is a vasoconstrictor, there is a theoretical risk of reduced placental blood flow, especially if absorption is increased through damaged mucosa or excessive dosing. Most guidelines recommend saline nasal sprays or rinses as the first-line treatment for nasal congestion in pregnancy, with decongestant sprays reserved for short-term use under medical advice when conservative measures fail.

Breastfeeding. It is not known whether xylometazoline is excreted in human breast milk. Given the uncertainty and the low therapeutic threshold in infants, Otrivin is generally not recommended during breastfeeding. If treatment is judged essential, the lowest effective dose should be used for the shortest possible period, and infants should be observed for any signs of drowsiness, feeding difficulty or agitation.

Driving and Operating Machinery

Otrivin is unlikely to affect the ability to drive or operate machinery at recommended doses. However, some patients may experience transient dizziness, headache or visual disturbances. If you are affected by such symptoms, refrain from driving and from performing tasks that require full alertness until the effects have resolved.

How Does Otrivin Interact with Other Drugs?

Although xylometazoline is applied topically to the nasal mucosa, small but pharmacologically relevant amounts can be absorbed into the systemic circulation. This means that clinically significant drug interactions are possible, particularly with medicines that affect noradrenergic neurotransmission, cardiovascular tone or central nervous system activity. The risk of interactions rises if the recommended dose is exceeded, if the nasal mucosa is inflamed or ulcerated, or if the product is used for longer than 7 to 10 days.

The most serious interaction involves monoamine oxidase (MAO) inhibitors, a class that includes phenelzine, tranylcypromine, isocarboxazid, moclobemide, and linezolid (which has MAOI-like activity). Combined administration can lead to a sudden, severe rise in blood pressure known as a hypertensive crisis, potentially resulting in headache, visual disturbance, chest pain, stroke or, rarely, death. Otrivin must not be used concurrently with MAOIs, nor within 14 days after the last dose of a MAOI.

Tricyclic and tetracyclic antidepressants — such as amitriptyline, nortriptyline, imipramine, maprotiline and mirtazapine — can potentiate the pressor effect of sympathomimetic amines by interfering with the reuptake of noradrenaline. Although the interaction is generally milder than with MAOIs, elevated blood pressure, palpitations and headache may occur. Concomitant use should be avoided where possible; otherwise, the lowest effective dose should be employed under medical supervision.

Concomitant administration of other sympathomimetics — including oral decongestants such as pseudoephedrine and phenylephrine, some asthma medications (e.g., ephedrine, theophylline), and certain stimulants — may produce additive cardiovascular and central nervous system effects. Patients should avoid combining multiple over-the-counter "cold and flu" preparations that already contain a decongestant.

Xylometazoline may partly counteract the effects of antihypertensive medicines, particularly beta-blockers, by causing transient vasoconstriction. Although this is rarely clinically significant at recommended doses, patients with poorly controlled hypertension should use Otrivin only under medical guidance. Similarly, concurrent use with ergot alkaloids (e.g., ergotamine used for migraine) may increase the risk of vasospasm.

What Is the Correct Dosage of Otrivin?

Always use Otrivin exactly as prescribed by your healthcare provider or as described in the patient information leaflet. The dose and frequency should not be exceeded, as higher doses do not increase the decongestant effect but substantially raise the risk of rebound congestion, mucosal damage and systemic side effects. When using a metered-dose pump spray, hold the bottle upright with the nozzle just inside the nostril, breathe in gently while pressing the pump firmly once, and release. Avoid sniffing sharply during administration, as this may deposit the solution too far back into the pharynx.

Adults and Adolescents (12 years and older)

Treatment should be continued only for as long as symptoms require, and in any case no longer than 7 consecutive days (with an upper safety limit of 10 days recommended by EMA and BNF guidance). For patients who experience chronic nasal congestion — whether due to allergic rhinitis, chronic sinusitis or nasal polyps — a longer-term management plan should be agreed with a healthcare professional, incorporating intranasal corticosteroids, antihistamines, saline irrigations and, where indicated, specialist investigation.

Children

Parents and caregivers should take particular care to measure pediatric doses accurately, store all nasal decongestant products out of the reach of children, and seek medical advice promptly if accidental ingestion or overdose is suspected. The risk of serious adverse effects is meaningfully higher in small children, and international poison-control statistics consistently list imidazoline decongestants among the more common causes of pediatric medication exposure incidents.

Elderly

Renal or Hepatic Impairment

Given the low systemic exposure achieved with correctly dosed intranasal xylometazoline, no formal dose adjustments are usually required for patients with mild to moderate renal or hepatic impairment. However, in severe impairment the pharmacokinetics of any absorbed drug may be altered, and cautious, short-term use under medical guidance is appropriate.

Missed Dose

If you forget a dose of Otrivin, simply take the next dose when needed for congestion. Do not apply a double dose to compensate for a missed application. Because the product is used symptomatically rather than on a strict schedule, missed doses are not clinically significant provided the maximum daily dose is never exceeded.

Overdose

Overdose can occur from excessive intranasal dosing or — more commonly in children — from accidental oral ingestion of the nasal solution. Symptoms may include marked drowsiness, extreme fatigue, pupillary constriction (miosis) or dilation (mydriasis), pallor, cold and clammy skin, reduced body temperature (hypothermia), slow heart rate (bradycardia), low blood pressure and respiratory depression. In severe cases, particularly in young children, coma and seizures can occur. Seek emergency medical attention immediately if overdose is suspected, or contact your national poison information center for advice. Treatment is supportive: airway protection, intravenous fluids and cardiovascular monitoring; there is no specific antidote.

What Are the Side Effects of Otrivin?

Like all medicines, Otrivin can cause side effects, although not everyone will experience them. The overall safety profile of xylometazoline at recommended intranasal doses is favorable, particularly for short-term use. The majority of adverse effects are mild, self-limiting and related to local irritation at the application site. Serious adverse events are rare and almost always associated with excessive dosing, prolonged use beyond the recommended 7–10 day limit, or accidental ingestion of the solution (especially in children).

It is useful to distinguish between expected transient local sensations — such as a brief stinging or cooling feeling on first application — and genuine adverse reactions that merit discontinuation. A mild initial burning sensation that resolves within a minute is common and clinically insignificant. By contrast, persistent burning, ulceration, frequent nosebleeds, increasing congestion between doses, or systemic symptoms such as palpitations, headache or dizziness warrant stopping the medication and seeking advice from a pharmacist or doctor.

The phenomenon of rhinitis medicamentosa deserves special attention. With prolonged topical use of xylometazoline or related imidazolines, alpha-adrenergic receptors in the nasal mucosa may become downregulated or desensitized. This results in rebound congestion — the nose becomes blocked again, often more severely, as the drug wears off. Patients respond by using the spray more frequently, creating a cycle of dependence. Clinical management involves gradual withdrawal (for example, using the spray in only one nostril at a time and weaning off), supported by intranasal corticosteroids and saline rinses. Complete recovery of normal mucosal function may take several weeks.

Systemic adverse effects such as tachycardia, hypertension, anxiety and tremor are almost always due to overdose or accidental oral ingestion, particularly in children. Because imidazoline-induced central alpha-2 receptor activation can cause profound sedation, pallor and bradycardia in small children even after ingesting small amounts, all bottles should be stored securely and out of reach. If any systemic symptom appears during regular use, discontinue the product and consult a clinician.

How Should You Store Otrivin?

Proper storage is essential to maintain the chemical stability of xylometazoline and to prevent microbial contamination of the nasal solution. Otrivin should be kept in its original packaging, protected from light and excessive heat. The recommended storage temperature is below 25°C (77°F). Do not freeze the solution, as freezing can alter the concentration and the integrity of the pump mechanism. Avoid storing the bottle in humid environments such as bathroom cabinets, particularly if the bottle is used infrequently.

Once the bottle has been opened for the first time, the manufacturer typically recommends that the product be used within a defined period — commonly 3 to 6 months depending on the specific formulation and preservative system. Preservative-free formulations may have shorter in-use stability. The in-use expiry period is printed on the carton or label. After this period, any remaining solution should be discarded even if the printed expiry date has not yet been reached.

Keep Otrivin out of the sight and reach of children at all times. The pump bottle's small volume and sometimes attractive packaging can lead to accidental ingestion, which is one of the more common reasons for pediatric poison-center contacts in relation to over-the-counter nasal sprays. Consider storing the product in a locked cabinet or in a container that is clearly out of reach for toddlers and preschool-age children.

Do not use Otrivin after the expiry date printed on the bottle and outer carton. The expiry date refers to the last day of the indicated month. Medicines should not be disposed of via wastewater or household waste. Return unused or expired nasal solution to your pharmacy for environmentally appropriate disposal via the local pharmaceutical take-back program. These measures help reduce pharmaceutical contamination of water supplies.

What Does Otrivin Contain?

Understanding the composition of a nasal medication is helpful for identifying potential allergens and making informed choices, particularly for patients with known sensitivities. Otrivin has a relatively simple pharmaceutical composition consisting of the active drug plus a small number of excipients designed to provide an isotonic, buffered, microbiologically stable and well-tolerated nasal solution.

Active Ingredient

Xylometazoline hydrochloride 1 mg/ml (equivalent to 0.1% w/v). Xylometazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic on alpha-adrenergic receptors. It is chemically distinct from ephedrine-type decongestants and does not release noradrenaline from storage vesicles — a property that contributes to its predictable, short-term topical action and relatively low potential for indirect systemic stimulation when used intranasally at recommended doses.

Typical Inactive Ingredients (Excipients)

• Sodium chloride (NaCl): Adjusts the tonicity of the solution to match that of body fluids (isotonicity), minimizing irritation and discomfort on application.
• Disodium phosphate / sodium dihydrogen phosphate: A buffer system that stabilizes the pH of the solution in a range that matches the nasal mucosa (approximately pH 5.5–7.0), preserving both drug stability and tolerability.
• Disodium edetate (EDTA): A chelating agent that binds trace metal ions and prevents them from catalyzing oxidative degradation of xylometazoline, thereby extending shelf-life and maintaining potency.
• Benzalkonium chloride: A preservative included in many multi-dose formulations to prevent microbial contamination after the bottle has been opened. Some patients are sensitive to benzalkonium chloride; for them, preservative-free formulations of Otrivin or similar xylometazoline products may be preferable.
• Purified water: The solvent base of the formulation.

Otrivin products may also contain additional excipients such as sorbitol, hypromellose (as a mucoadhesive humectant that helps the solution remain in contact with the nasal mucosa longer) or menthol/eucalyptus (in "Menthol" sub-variants, to provide a cooling, decongestant-like sensation). The exact excipient list depends on the specific product variant and country of marketing; always consult the package leaflet supplied with your bottle for the definitive composition.

Packaging

Otrivin is typically supplied in small multi-dose bottles of 10 ml fitted with a metered-dose pump spray or a dropper, packaged in a cardboard carton with a patient information leaflet. Single-dose preservative-free vials and larger bottles are available in some markets. The packaging is designed to protect the solution from light and contamination while the pump mechanism delivers a consistent, measured dose per actuation.

Medical Editorial Team

This article was written and reviewed by iMedic's medical editorial team, composed of licensed physicians and clinical pharmacologists with expertise in otorhinolaryngology, allergology and the pharmacology of sympathomimetic agents.